The Wnt-dependent signaling pathways as target in oncology drug discovery
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Our current understanding of the Wnt-dependent signaling pathways is mainly based on studies performed in a number of model organisms including, Xenopus, Drosophila melanogaster, Caenorhabditis elegans and mammals. These studies clearly indicate that the Wnt-dependent signaling pathways are conserved through evolution and control many events during embryonic development. Wnt pathways have been shown to regulate cell proliferation, morphology, motility as well as cell fate. The increasing interest of the scientific community, over the last decade, in the Wnt-dependent signaling pathways is supported by the documented importance of these pathways in a broad range of physiological conditions and disease states. For instance, it has been shown that inappropriate regulation and activation of these pathways is associated with several pathological disorders including cancer, retinopathy, tetra-amelia and bone and cartilage disease such as arthritis. In addition, several components of the Wnt-dependent signaling pathways appear to play important roles in diseases such as Alzheimer's disease, schizophrenia, bipolar disorder and in the emerging field of stem cell research. In this review, we wish to present a focused overview of the function of the Wnt-dependent signaling pathways and their role in oncogenesis and cancer development. We also want to provide information on a selection of potential drug targets within these pathways for oncology drug discovery, and summarize current data on approaches, including the development of small-molecule inhibitors, that have shown relevant effects on the Wnt-dependent signaling pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233 · cited 1×
“HDAC inhibitors The recruitment of histone acetyltransferases (HATs) and histone deacetylases (HDACs) is considered to be a key element in the dynamic regulation of many genes regulating cell proliferation and differentiation during normal development and carcinogenesis [122].”
BackgroundThe cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Phosphorylated CREB binds specifically to the nuclear protein CBP
Chrivia, J. C., Kwok, R. P. S., Lamb, N., Hagiwara, M., Montminy, M. R., & Goodman, R. H. (1993) · Nature · doi:10.1038/365855a0 · Cited by 2,052 · cited 5×
“CBP or its closely related homolog p300 were initially identified in protein interaction assays, first through their association with the transcription factor CREB [172] and later through their interaction with the adenoviral-transforming protein E1A [173].”
BackgroundInfluentialThe β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
WNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763
A vision for the future of genomics research
Collins, F. S., Green, E. D., Guttmacher, A. E., Guyer, M. S., & on behalf of the US National Human Genome Research Institute (2003) · Nature · doi:10.1038/nature01626 · Cited by 1,752 · cited 1×
“With the advent of high-throughput methods that evaluate gene-expression in tumors [86–88], the discovery of genes that are differentially expressed has been increasing exponentially.”
BackgroundHigh Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591
Secreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584 · cited 1×
“The second group, consisting of the Dickkopf (DKK) family, inhibits Wnt signaling by binding to the LRP5/LRP6 component of the Wnt receptor complex [8].”
BackgroundHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · cited 1×
“HDACs are usually subunits of multiprotein complexes and HDAC inhibitors are considered as very promising drug candidates for the treatment of leukemia, and various other forms of cancer [123–125].”
BackgroundCaught up in a Wnt storm: Wnt signaling in cancer
Giles, R. H., van Es, J. H., & Clevers, H. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00005-2 · Cited by 1,482 · cited 1×
“As the downstream components were identified, more studies have found evidence linking the different components of these pathways to cancer [41–44] as well as other indications (Table 1).”
BackgroundDrosophila Tcf and Groucho interact to repress Wingless signalling activity
Cavallo, R. A., Cox, R. T., Moline, M. M., Roose, J., Polevoy, G. A., Clevers, H., Peifer, M., & Bejsovec, A. (1998) · Nature · doi:10.1038/26982 · Cited by 730
Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation
Habas, R., Dawid, I. B., & He, X. (2003) · Genes & Development · doi:10.1101/gad.1022203 · Cited by 603
Van Wesenbeeck, L., Cleiren, E., Gram, J., Beals, R. K., Bénichou, O., Scopelliti, D., Key, L., Renton, T., Bartels, C., Gong, Y., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/368277 · Cited by 568
Kühl, M., Sheldahl, L. C., Malbon, C. C., & Moon, R. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12701 · Cited by 517
Modulation of Embryonic Intracellular Ca2+Signaling byWnt-5A
Slusarski, D. C., Yang-Snyder, J., Busa, W. B., & Moon, R. T. (1997) · Developmental Biology · doi:10.1006/dbio.1996.8463 · Cited by 404 · cited 1×
“The Wnt/Ca2+ pathway regulates cell adhesion and motility [24], and is mediated through release of intracellular Ca2+ upon Wnt stimulation, and involves activation of protein kinase C (PKC) and calcium/calmodulin-dependent kinase II (CamKII) [25–27], leading to the regulation of the Ca2+-responsive transcription facto…”
BackgroundMlodzik, M. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(02)02770-1 · Cited by 341 · cited 1×
“(JNK) respectively [34–36].”
The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus embryos
Saneyoshi, T., Kume, S., Amasaki, Y., & Mikoshiba, K. (2002) · Nature · doi:10.1038/417295a · Cited by 322 · cited 1×
“The Wnt/Ca2+ pathway regulates cell adhesion and motility [24], and is mediated through release of intracellular Ca2+ upon Wnt stimulation, and involves activation of protein kinase C (PKC) and calcium/calmodulin-dependent kinase II (CamKII) [25–27], leading to the regulation of the Ca2+-responsive transcription facto…”
BackgroundDjiane, A., Riou, J.-F., Umbhauer, M., Boucaut, J.-C., & Shi, D.-L. (2000) · Development · doi:10.1242/dev.127.14.3091 · Cited by 316
Wharton, K. A. (2003) · Developmental Biology · doi:10.1006/dbio.2002.0869 · Cited by 315 · cited 1×
“Data suggest that Dvl proteins organize dynamic, pathway-specific subcellular signaling complexes that ensure correct information routing, signal amplification, and dynamic control through feedback regulation [156].”
BackgroundDiscovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Wagman, A., Johnson, K., & Bussiere, D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452668 · Cited by 153 · cited 1×
“Recent crystal structures, including the active (phosphorylated Tyr-216) form of GSK3β, provided a wealth of structural information and greater understanding of GSK3’s unique regulation and substrate specificity [160].”
Background
Cited by
Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review
Chiurillo, M. A. (2015) · World Journal of Experimental Medicine · doi:10.5493/wjem.v5.i2.84 · Cited by 317
Utilizing graph machine learning within drug discovery and development
Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab159 · Cited by 313
Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313
Helping Wingless take flight: how WNT proteins are secreted
Hausmann, G., Bänziger, C., & Basler, K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2141 · Cited by 147
Flavonoids: Potential Wnt/beta-catenin signaling modulators in cancer
Amado, N. G., Fonseca, B. F., Cerqueira, D. M., Neto, V. M., & Abreu, J. G. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.003 · Cited by 125
Metadata
- Authors
- Janssens, N., Janicot, M., & Perera, T.
- Venue
- Investigational New Drugs
- Published
- 2006-01-28
- Volume
- 24
- Issue
- 4
- Pages
- 263-280
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2013209137
- Cited by
- 73
- References
- 21
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.